SUPERNUS PHARMAC.DL -,001 revenue for the last year amounted to 550.42 M EUR, the most of which — 550.42 M EUR — came from its highest performing source at the moment, Treatment of Central Nervous System Diseases, the year earlier bringing 623.44 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought SUPERNUS PHARMAC.DL -,001 550.42 M EUR, and the year before that — 623.44 M EUR.